A recent study indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide may regain shed pounds much more quickly than those who halt conventional diet and exercise plans.
Findings released in a major medical journal points out that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit.
"Individuals buying such drugs must be aware of the danger of rapid weight regain when the treatment is stopped," stated expert Dr. Susan Jebb.
This pace of recovery suggests a reversion to original weight within about one and a half years.
Comparing Treatments
The research, which looked at 37 of studies involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Researchers note that people who lose weight through lifestyle changes alone typically see a less rapid creep back—perhaps 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Experts believe the way of the drugs is key to understanding the heightened rebound.
The injections imitate a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication means hunger is unsuppressed, making overeating much more probable."
A Chronic Condition?
The NHS recommend the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, given the likelihood of weight regain, the therapy is often ongoing.
This opinion is reinforced by pharmaceutical companies, who say that the results "highlight the chronic nature of obesity," similar to managing diseases like hypertension.
Patient Accounts
Individuals who have stopped the jabs report a sudden resurgence of appetite.
"I experienced a switch flipping and I was suddenly extremely hungry," described a patient.
The struggle is worsened if patients have not adopted sustainable lifestyle or habit changes during treatment.
Widespread Use
Survey data indicate that a significant number of people in the UK have tried these injections in the last 12 months, with demand being substantial.
- Use is greater among females than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Finally, experts caution that while GLP-1 drugs are potent tools for weight loss, they are not a standalone fix and long-term success likely depends on combined behavioural management.
